Propaganda in Israel-Hamas conflict, iOS 17 Bluetooth flaws, soaring global borrowing costs, Alzheimer's drug milestone
Today ChatGPT read 1171 top news stories. After removing previously covered events, there are 4 articles with a significance score over 7.
[7.6] Online world war escalates as Iran, Russia, and China support Hamas. — The New York Times [$]
The conflict between Israel and Hamas has escalated into an online world war, with Iran, Russia, and China using state media and major social networking platforms to support Hamas and undermine Israel. The deluge of online propaganda and disinformation is larger than anything seen before, with millions of people around the world being exposed to it. The content is emotionally charged, politically biased, and often false, raising fears that it could inflame a wider conflict.
[7.2] iOS 17 iPhones vulnerable to Bluetooth attack, disable Bluetooth for protection. — The Verge
Security researchers have discovered that iPhones running iOS 17 are vulnerable to a Bluetooth attack using a Flipper Zero device, which can crash the phone. The attack involves sending a combination of Bluetooth low energy alerts to nearby iPhones. The attack does not affect iPhones running older iOS versions, and a similar attack can also be used on Android devices and Windows laptops. The only reliable way to protect against the attack on iOS 17 is by disabling Bluetooth.
[7.0] Investors warn of higher borrowing costs, impacting public finances. — Financial Times [$]
Investors are warning governments to expect higher borrowing costs in the coming years, which will impact public finances and limit states' ability to respond to crises. Government bond prices have dropped on both sides of the Atlantic, reflecting a growing acceptance that interest rates will need to stay high to dampen inflation. The interest bill for G7 countries is expected to increase from $905 billion in 2018 to $1.5 trillion by 2026.
[7.2] Cleveland Clinic administers first drug for Alzheimer's treatment. — Cleveland Clinic Newsroom
On November 2, 2023, the Cleveland Clinic Lou Ruvo Center for Brain Health administered its first infusion of the anti-amyloid drug, lecanemab, for the treatment of mild Alzheimer's disease. The drug received traditional approval from the FDA in July and is the first therapy proven to slow the progression of the disease, not just treat its symptoms.
Want to read more?
See additional news on newsminimalist.com.
Thanks for reading us and see you tomorrow,